Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104524 | 1.00 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4120080 | 1.00 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4119818 | 1.00 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4421691 | 0.85 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL4102770 | 0.85 | CNR2 (1.00) | CNR1CNR2 | |
| SCHEMBL4114760 | 0.85 | CNR2 (1.00) | CNR1CNR2 | |
| SCHEMBL4115813 | 0.84 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL4112785 | 0.84 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL4110891 | 0.84 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL4421695 | 0.83 | CNR2 (0.72) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2026087339-A1 | RUBBER PROCESS OIL | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2026-04-30 | — | — | WO | disclosed |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12404293-B2 | Method for producing glycan, building block for gylican synthesis, and compound | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2025-09-02 | — | — | US | disclosed |
| EP-4157215-B1 | METHOD FOR SOLUBILIZING NATURAL, ENDOGENOUS AND SYNTHETIC CANNABINOIDS | ATHENION AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| EP-4577247-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12324435-B2 | Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides | BASF SE (DE) | 2025-06-10 | — | — | US | disclosed |
| US-20230210786-A1 | METHOD FOR SOLUBILIZING NATURAL, ENDOGENOUS AND SYNTHETIC CANNABINOIDS | ATHENION AG (CH) | 2023-07-06 | — | — | US | disclosed |
| WO-2023125745-A1 | ANTI-βKLOTHO ANTIBODY AND USE THEREOF | 上海津曼特生物科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| EP-3278100-B1 | METHODS AND USES COMPRISING SOLID PHASE EXTRACTION, DERIVATIZATION WITH CROWN ETHERS, AND MASS SPECTROMETRY | TECAN SP INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230167071-A1 | COMPOUNDS WITH ANTIMALARIAL ACTIVITY | UNIVERSITY OF PUERTO RICO (PR) | 2023-06-01 | — | — | US | disclosed |
| US-20230143273-A1 | METHOD FOR PRODUCING GLYCAN, BUILDING BLOCK FOR GYLICAN SYNTHESIS, AND COMPOUND | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2023-05-11 | — | — | US | disclosed |
| US-11513132-B2 | Solid phase extraction, derivatization with crown ethers, and mass spectrometry, methods, reagents and kits | TECAN SP, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| WO-2022172781-A1 | CURABLE COMPOSITION | 住友化学株式会社 | 2022-08-18 | — | — | WO | disclosed |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324435-B2 | Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides | NMT2, NAPRT, NAMPT | CNR1 2951/4885CNR2 2003/4885 |
| US-20230167071-A1 | COMPOUNDS WITH ANTIMALARIAL ACTIVITY | GSTA2, GSTP1, GSTA1 | CNR1 4414/4885CNR2 4500/4885 |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | NMT2, NAPRT, NAMPT | CNR1 2951/4885CNR2 2003/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885 |
| US-11513132-B2 | Solid phase extraction, derivatization with crown ethers, and mass spectrometry, methods, reagents and kits | CYP2C8, CES2, UGT1A8 | CNR1 822/4885CNR2 837/4885 |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885 |
| US-12404293-B2 | Method for producing glycan, building block for gylican synthesis, and compound | OSTC, GYPA, AGL | CNR1 4837/4885CNR2 4797/4885 |
| US-20230143273-A1 | METHOD FOR PRODUCING GLYCAN, BUILDING BLOCK FOR GYLICAN SYNTHESIS, AND COMPOUND | OSTC, GYPA, AGL | CNR1 4837/4885CNR2 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.